In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.
|Translated title of the contribution||Liquid Biopsy in Breast Cancer|
|Journal||Tumor Diagnostik und Therapie|
|Number of pages||12|
|Publication status||Published - 01.06.2021|
Research Areas and Centers
- Centers: University Cancer Center Schleswig-Holstein (UCCSH)
- Research Area: Luebeck Integrated Oncology Network (LION)